Anika Therapeutics (ANIK) EPS (Diluted) Growth (3y) (2013 - 2025)
Anika Therapeutics (ANIK) EPS (Diluted) Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 3.25% |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | 2.66% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 11.56% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -35.09% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 13.29% |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | 36.48% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Anika Therapeutics | 285.93 Mn | 247.52 Mn | 21.24 Mn | 48.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -29.11% |
| Sep 30, 2025 | 30.17% |
| Jun 30, 2025 | 30.82% |
| Mar 31, 2025 | 31.72% |
| Dec 31, 2024 | -81.28% |
| Sep 30, 2024 | -274.30% |
| Jun 30, 2024 | -28.19% |
| Mar 31, 2024 | -42.36% |
| Dec 31, 2023 | 44.24% |
| Sep 30, 2023 | 0.33% |
| Jun 30, 2023 | 29.94% |
| Mar 31, 2023 | -55.36% |
| Dec 31, 2022 | 16.86% |
| Sep 30, 2022 | -34.73% |
| Jun 30, 2022 | -31.84% |
| Mar 31, 2022 | -38.18% |
| Dec 31, 2021 | -33.64% |
| Sep 30, 2021 | -58.53% |
| Jun 30, 2021 | -12.94% |
| Mar 31, 2021 | 34.47% |